Vitality Biopharma, Inc. introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC.     Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which enable targeted delivery of THC to the large intestine. THC has been previously reviewed and approved by the U.S. Food & Drug Administration (FDA) under the name dronabinol, and has been established as safe and effective for use with appetite stimulation and for treatment of nausea and vomiting. Vitality’s cannabosides could enable oral delivery of large concentrations of cannabinoids in order to provide therapeutic benefits while reducing or eliminating psychoactivity by limiting entry of THC into the bloodstream or brain.  Vitality is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation, and plans to complete a first-in-man clinical study in the first half of 2018. The treatment indications the Company plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome, a severe form of opiate-induced abdominal pain. Independent clinical trial results suggest that THC can help induce remission in drug-resistant Crohn’s disease and that the vast majority (75% or more) of IBD patients report improvement in visceral pain and abdominal cramping with cannabinoid treatment.  More than 1.4 million Americans have been diagnosed with IBD, which includes Crohn’s disease and ulcerative colitis. Most IBD patients are diagnosed before age 30 and require life-long treatment.